4D Molecular Therapeutics announced interim data from the Phase 1/2 AEROW clinical trial evaluating Aerosolized 4D-710 for treatment of cystic fibrosis lung disease. Participants with cystic fibrosis in this clinical trial do not have the option of treatment with currently available disease modifying therapies and therefore have high unmet need. Initial results from the AEROW study showed that 4D-710 resulted in CFTR expression in lung airways that significantly exceeded target profile.

$20 Million. 4DMT has been supported by the CF Foundation since 2016, including a 2017 research agreement ("CF Foundation Agreement") to discover and develop optimized next generation AAV vectors for use in genetic medicines targeting lung airway cells in people with CF. In August 2023 the Company executed an amendment to the CF Foundation Agreement increasing the funding commitment under that agreement by $2.8 million to a total of $6.3 million, which covers anticipated spend for further development of aerosolized lung epithelium gene delivery vectors.

In 2020 and 2021, the CF Foundation invested $14 million in 4DMT equity to support the development of 4D-710. The complications of the disease result in progressive loss of lung function and hospitalizations, and ultimately lead to end-stage respiratory failure. 4D-150, 4D-310, 4D-125, and 4D-110 are product candidates in clinical development and have not yet been approved for marketing by the US FDA or any other regulatory authority.